Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brilinta Panel Leaves FDA With The Task Of Crafting Labeling That Describes Poor U.S Efficacy Results

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Cardiovascular and Renal Drugs Advisory Committee votes 7-1 in favor of ticagrelor's approval for acute coronary syndromes despite rejecting AstraZeneca's aspirin-dosing theory as the sole cause of lack of benefit in the U.S. population.

You may also be interested in...



Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?

FDA appears to have come around to the "aspirin hypothesis" offered by AstraZeneca PLC to explain poor results for North American patients who took the blood-thinner Brilinta, though labeling takes a somewhat cautious approach that reflects initial concerns about that explanation.

Brilinta Approval Shows AstraZeneca's Success With Aspirin Theory, But Can It Change The Market?

FDA appears to have come around to the "aspirin hypothesis" offered by AstraZeneca PLC to explain poor results for North American patients who took the blood-thinner Brilinta, though labeling takes a somewhat cautious approach that reflects initial concerns about that explanation.

AstraZeneca Gives FDA More Data On Brilinta Interaction With High-Dose Aspirin

In replying to FDA's December "complete response," company reaffirms its view that U.S. efficacy in the pivotal PLATO study was undercut by high doses of concomitant aspirin.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel